What is Havn Life?
Havn Life Sciences Inc. operates at the intersection of biotechnology and mental wellness, focusing on the development of psychedelic medicine. The company is actively building a comprehensive supply chain dedicated to the extraction, formulation, and delivery of compounds derived from fungi and plant-based sources. By prioritizing evidence-informed research, Havn Life aims to provide sustainable, innovative therapies for individuals seeking alternatives to traditional mental health treatments. Their core competency lies in the standardization of microdosing protocols, which are increasingly viewed as a critical frontier in psychiatric care and cognitive wellness.
How much funding has Havn Life raised?
Havn Life has raised a total of $6.5M across 3 funding rounds:
Debt
$5M
Debt
$1.1M
Private Equity
$420K
Debt (2020): $5M with participation from Capital , Inc.
Debt (2022): $1.1M led by Alpha Blue Ocean
Private Equity (2022): $420K supported by Alpha Blue Ocean
Key Investors in Havn Life
Alpha Blue Ocean
Alpha Blue Ocean is an investment manager specializing in debt and equity financing for publicly listed companies across diverse sectors, including healthcare and technology.
Capital , Inc.
An institutional investor providing debt financing to support the early-stage growth and operational requirements of the company.
What's next for Havn Life?
With the recent infusion of capital, Havn Life is expected to intensify its focus on clinical research and the expansion of its proprietary supply chain. The strategic deployment of these funds will likely target the optimization of formulation technologies and the scaling of production capabilities to meet the growing demand for clinical-grade psychedelic materials. As the company moves deeper into its lifecycle, the focus will shift toward securing regulatory milestones and establishing partnerships with research institutions to validate the efficacy of their therapeutic models. This phase of development is critical for transitioning from research-heavy operations to a more commercially viable, evidence-backed market participant.
See full Havn Life company page
